Top 10 Drug Patents Expiring In The Year 2021
Amag Pharma’s drug named Feraheme for the treatment of iron deficiency anaemia was in 10th rank. In the year 2020, it enabled the firm to achieve sales of around $150 million. But its patent expiry date was this month only, which means July 2021.
Mallinckrodt’s Amitiza was made for the treatment of constipation and irritable bowel syndrome in patients. Its 2020 US Sales was 180 million US dollars. And its patent expiry date was January 2021.
Allegan’s Saphris, which was indicated for the treatment of schizophrenia and bipolar disorder, its 2020 sales, were not disclosed. The patent expiry date of this drug was December 2020.
Pfizer’s Sutent bagged 7th rank, developed for patients with gastrointestinal stromal tumours, advanced renal cell carcinoma and pancreatic neuroendocrine tumours. Its 2020 US Sales was 223 million US dollars. Sutent’s patent expiry date lies in August 2021.
Sunovion Pharma’s drug named Brovana treated patients with chronic obstructive pulmonary disease. In 2020, approx, 275 million dollars of sales were made from this drug. Its patent expiry date was July 2021.
Teva had launched Narcan to treat patients with opioid overdose. With the launch of this drug, the company made 311 million US dollars. Its patent expiry date was June 2021.
Lundbeck’s neurogenic orthostatic hypotension drug named Northera enabled the company to achieve the sale of 416 million US dollars. This medicine patent expiry date was February 2021.
Amarin’s Vascepa which cured patients with hypertriglyceridemia and cardiovascular disease scored 3rd rank. It helped the company to make the sale of $598 million. This drug patent expiry date was November 2020.
AbbVie’s Bystolic scored 2nd rank, whose sales were undisclosed. The pharma firm developed this drug for high BP patients. The patent expiry date of this drug lies in September 2021
Roche’s Lucentis achieved 1st rank. It worked for patients with Wet age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema and diabetic retinopathy. Its patent expiry was somewhere in July 2021.